RESUMO
Objective To use the liquid phase coprecipitation method for preparing gemcitabine magnetic nanoparticles to the pouch,and explore the preparation process in a number of conditions. Methods The effect of different stirring speeds,Fe3+/Fe2+ratio,pH,temperature of Fe3O4 powder and emulsification condition,ultrasonic time,curing temperature on the preparation of target?ed magnetic nanoparticles were observed. Results The preparation of Fe3O4 nanoparticles was as follows:800 r/ min of stirring speed,1.7∶1 Fe3+/Fe2+ratio,pH=9,the reaction temperature of 60℃,and the 5∶40 water/oil compared,ultrasonic time of 10 min, 100℃curing temperature. Conclusion Fe3O4 powder with small particle size,high purity,and no agglomeration are prepared,the stability of the gemcitabine magnetic nanoparticles capsule is good.
RESUMO
Objective To study the significance of the prognosis assessment by acute physiology and chronic health evaluation (APACHE Ⅱ ),sequential organ failure assessment (SOFA) score,clinical pulmonary infection score(CPIS) and multiple organ dysfunction syndrome (MODS) score in the patients of ventilator-associated pneumonia (VAP). Methods The clinical data of 68 cases with VAP in the ICU or RICU were studied. APACHE Ⅱ , SOFA and MODS scores on admission and APACHE Ⅱ , SOFA, CPIS and MODS scores on the first 24-hour of VAP diagnosis were recorded. The area under the receiver operating characteristic curve(AUROC ) and Logistic regression were used to estimate the prognostic ability by the four kinds of scoring systems. Results The APACHE Ⅱ , CPIS, MODS and SOFA scores on the first 24-hour of VAP diagnosis were significantly higher in non-survivors than those in survivors. AUROC of APACHE Ⅱ ,SOFA,MODS and CPIS respectively were 0.80,0.75,0.73,0.71. Logistic regression analysis showed that only APACHE Ⅱ> 18 scores on the first 24-hour of VAP diagnosis was an independent predictor of the mortality (OR: 5.7,95% CI: 1.9 - 20.0, P = 0.013). Conclusion The APACHE Ⅱ on the first 24-hour of VAP diagnosis may be a useful index in predicting progress of patients with VAP.